Skip to main content

Table 1 Differential expression studies between NEPC & prostatic adenocarcinoma

From: Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma

   NEPC samples AdCa samples Gene-list
Study Type U M L P U M L P GS Up Dn
WCMC mCRPC T 10 10 3 2 25 18 9 7   1226 1132
WCMC 2011 T/Xa 7 6   1 30    30 5-9 494 460
UW mCRPC T 6 7 3   41 37 24    126 29
LuCaP xeno X 3 2 1 1 16 5 11 4   17 16
MDA xeno X 3   4 1 3   1 2 9 45 67
VPC xeno X 1    1 6   1 11   254 185
VPC 2012 T/X* 1 3    3   2 3 7-9 202 127
JHU 2009 T 1    1 1    1 7 41 41
Total   29     114      1782 1785
  1. Legend: (Notation): U: unique patients, T: tumor, X: xenograft, P: primary, M: metastases, L: bladder, rectum, or lymph node, GS: Gleason score, Up/Dn: size of gene-lists up/down-expressed in NEPC. (a): WCMC 2011 and VPC 2012 each contained one xenograft NEPC sample. (Notes): WCMC studies shared 2 NEPC patients, while UW mCRPC and LuCaP studies shared 1 NEPC patient. Adenocarcinomas with NE differentiation were grouped with NEPCs in WCMC mCRPC, with adenocarcinomas in MDA xeno, and with either cohort in UW mCRPC depending on IHC status of chromogranin and synaptophysin (NEPC when both positive). The VPC xeno gene-list cross-referenced other studies and consisted of genes with expression changes following transdifferentiation in a xenograft model, concomitant alterations in the same direction prior to transdifferentiation relative to adenocarcinomas, and exhibiting the same trend in WCMC 2011. The JHU study consisted of a single patient tumor with adjacent small cell carcinoma and adenocarcinoma components